|Application ||WB, IHC|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||22963 Da|
|Other Names||Protein phosphatase 1 regulatory subunit 1B, DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein, PPP1R1B, DARPP32|
|Target/Specificity||A synthetic peptide corresponding to residues near the N-term of human DARPP-32 was used as immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DARPP-32 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Inhibitor of protein-phosphatase 1.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The 32kDa dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein (DARPP-32) can either function as a serine/threonine kinase or as a serine/threonine phosphatase depending upon which particular amino acid residue is phosphorylated (1). When phosphorylated by protein kinase A (PKA) at threonine 34, DARPP-32 becomes a potent inhibitor of protein phosphatase-1 (2-3). Alternatively, when phosphorylated at threonine 75 by cyclin-dependent kinase 5(Cdk5), DARPP-32 is converted into an inhibitor of PKA (1). DARPP-32 and truncated DARPP (t-DARPP) are overexpressed in gastric cancers (4).
1. Bibb et al. Nature 402: 669-671, 1999.
2. Greengard, P.; Allen, P. B.; Nairn, A. C. : Neuron 23: 435-447, 1999.
3. Hemmings, H. C., Jr.; Greengard, P.; Tung, H. Y.; Cohen, P. : Nature 310: 503-505, 1984.
4. El-Rifai, W.; Smith, M. F., Jr.; Li, G.; Beckler, A.; Carl, V. S.; Montgomery, E.; Knuutila, S.; Moskaluk, C. A.; Frierson, H. F., Jr.; Powell, S. M. :Cancer Res. 62: 4061-4064, 2002.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.